Corporate Presentations

DateTitle
04/04/17
Download Documentation Company Update (April)
09/08/16
Download Documentation PAINWeek 2016: Local Administration of HTX-011, a Long-Acting Biochronomer®-Based Bupivacaine/Meloxicam Combination, in Hernia Repair: Preliminary Results of an Interim Analysis
09/08/16
Download Documentation PAINWeek 2016: Local Administration of HTX-011, a Long-Acting Biochronomer®-Based Bupivacaine/Meloxicam Combination, in Hernia Repair Provides Similar Initial Results Whether Injected or Instilled
08/01/16
Download Documentation HTX-011 Positive Phase 2 Bunion and Hernia Topline Results
12/09/15
Download Documentation San Antonio Breast Cancer Symposium December 2015 - Phase 3 Comparison of APF530 vs Ondansetron, Each in a Guideline-Recommended 3-Drug Regimen for the Prevention of CINV Due to AC-Based HEC Regimens: a Post Hoc Subgroup Analysis of the MAGIC Trial
09/26/15
Download Documentation ASCO Breast Cancer Symposium September 2015: Phase 3 Study of APF530 vs Ondansetron with a Neurokinin 1 Antagonist + Corticosteroid in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: MAGIC Trial
09/22/15
Download Documentation A Phase 2 Study of HTX-011 in the Management of Post-Operative Pain - Positive Top-Line Results
05/28/15
Download Documentation MAGIC: A Phase 3 Study of SUSTOL® in Patients Receiving Highly Emetogenic Chemotherapy - Positive Top-Line Results
03/19/15
Download Documentation Heron Post-Operative Pain Program Phase 1 Study
06/01/14
Download Documentation ASCO Annual Meeting: Randomized, Double-Blind Phase 3 Trial of Extended-Release Granisetron (APF530) Versus Palonosetron for Preventing Chemotherapy-Induced Nausea and Vomiting Associated With Moderately or Highly Emetogenic Chemotherapy
06/01/14
Download Documentation American Society of Clinical Oncology Annual Meeting: Randomized, Double-Blind Phase 3 Trial of Extended-Release Granisetron (APF530) Versus Palonosetron for Preventing Chemotherapy-Induced Nausea and Vomiting
06/29/12
Download Documentation Patient Satisfaction With Control of Emesis Following Chemotherapy: Comparison of APF530, a Subcutaneous Extended-Release Formulation of Granisetron, Versus Intravenous Palonosetron
09/14/09
Download Documentation 2009 Supportive Oncology Conference: Phase 3 Study Of Sustained Release Granisetron (APF530) Compared To Palonosetron For The Prevention Of Chemotherapy-Induced Nausea And Vomiting (CINV)
06/01/09
Download Documentation American Society of Clinical Oncology Annual Meeting: Phase 3 Study Of Sustained Release Granisetron (APF530) Compared To Palonosetron For The Prevention Of Chemotherapy-Induced Nausea And Vomiting (CINV)